A firm received the following critical 483 in response to their Stability Program failures. This blog post connects to the importance of Annual Product Reviews at this point in the year. The 483 reads:
…..The written stability testing program is not followed.
Specifically, according to your Quality Agreement with the … product owner, your firm is responsible for conducting stability studies for … to support the product’s 2-year expiry period. However, your firm stopped testing … stability samples after your CRT stability chamber (Asset #… ) was found to be out-of-specificationon…and tagged “out of order”….
Batch # … was in the CRT stability chamber at the time, for which you had only generated stability data out to the 12-month time point. No further stability testing was conducted on this stability batch.Additionally, … … batches (lot# … manufactured on …, lot# … manufactured on … and lot# … manufactured on …) were manufactured and not put on accelerated or CRT stability as required by the client for the annual stability sample data.
All of the aforementioned … batches were released and distributed to the US market.
You have not generated any annual stability data for the last 2 years for the … batches manufactured during that time period. Your firm failed to notify the product owner that you stopped conducting stability studies for their product 2 years ago, and failed to place … samples on stability within the required 30 calendar days from batch release as outlined in the Quality Agreement.
This failure was a multi-year breakdown in stability execution, communication, and quality agreement governance, culminating in the release of commercial product to the U.S. market without required stability support.
At the core of the observation is a disconnect between the written stability program and actual practice. When stability studies are not conducted as designed, FDA is left with unanswered questions:
- Is the product still meeting specifications at expiration?
- Are degradation products increasing?
- Is the labeled shelf life scientifically justified?
- Were patients exposed to potentially sub-potent or degraded drug product?
Stability data is the scientific justification for expiry dating, labeling, and patient safety. From our perspective at GMP Trends, this observation aligns with broader trends across recent 483’s and Warning Letters. Common contributors for mistakes include:
- Over-reliance on a single stability chamber without redundancy
- Inadequate stability contingency planning
- Weak deviation escalation pathways
- Poor integration between Production, Quality, and Regulatory
- Treating stability as a technical function, not a compliance commitment
Stability failures often surface years after the original breakdown, when there is no easy corrective path. In this case, FDA did not need evidence of product failure. The absence of data itself was sufficient to support the observation.
This 483 also highlights a missed opportunity within the firm’s Annual Product Review process. APR’s are intended to confirm that products continue to be manufactured and controlled as approved, and not just merely to summarize deviations and test results. Had the APR process included a structured review of Quality Agreement obligations, particularly those related to stability testing, this failure would likely have been identified early.
An enhanced APR process should include explicit confirmation that contractual quality commitments are being executed. At a minimum, firms should be asking:
- Were all required stability studies initiated and maintained?
- Was annual stability data generated for each commercial product?
- Do executed activities align with Quality Agreement responsibilities?
- Were any commitments missed, and if so, were clients notified?
Give us a call anytime and schedule a call at https://gmptrends.com/schedule-a-demo/ to learn more about the GMP Trends Platform.
Our paid reports will significantly benefit your awareness of FDA inspection trends.
